Table 1.

Patient characteristics

CharacteristicPazopanib (N = 221)Sunitinib (N = 232)
Median age, y (range)62 (30–86)62 (33–86)
Sex, n (%)
 Male158 (71)178 (77)
 Female63 (29)54 (23)
Prior nephrectomy, n (%)191 (86)205 (88)
KPS, n (%)
 70 or 8057 (26)60 (26)
 90 or 100164 (74)169 (74)
LDH, n (%)
 >1.5× ULN17 (8)11 (5)
 ≤1.5× ULN204 (92)214 (95)
Metastatic sites at baseline, n (%)
 ≤2151 (68)152 (65)
 >270 (32)80 (34)
MSKCC risk category, n (%)
 Favorable64 (29)55 (24)
 Intermediate127 (57)142 (61)
 Poor26 (12)24 (10)
 Unknown4 (2)11 (5)

Abbreviation: ULN, upper limit of the normal range.